ArticleBritish journal of cancer2001
E-cadherin as a prognostic indicator in primary breast cancer.
Article in British journal of cancer, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- TGFα-EGFR pathway in breast carcinogenesis, association with WWOX expression and estrogen activation.Journal of applied genetics · 2022Article
- HS2ST1-dependent signaling pathways determine breast cancer cell viability, matrix interactions, and invasive behavior.Cancer science · 2020Article
- A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer.Breast cancer research : BCR · 2020Article
- Expression of human endogenous retrovirus-K is strongly associated with the basal-like breast cancer phenotype.Scientific reports · 2017Article
- E-cadherin re-expression shows in vivo evidence for mesenchymal to epithelial transition in clonal metastatic breast tumor cells.Oncotarget · 2016Article
- Retrospective analysis of metastatic behaviour of breast cancer subtypes.Breast cancer research and treatment · 2015Article
- Aberrant P-cadherin expression is associated to aggressive feline mammary carcinomas.BMC veterinary research · 2014Article
- Article
- MDA-7/IL-24 inhibits cell survival by inducing apoptosis in nasopharyngeal carcinoma.International journal of clinical and experimental medicine · 2014Article
- Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells.The American journal of pathology · 2011Article
- An immunohistochemically positive E-cadherin status is not always predictive for a good prognosis in human breast cancer.British journal of cancer · 2010Article
- Hypoxia, Snail and incomplete epithelial-mesenchymal transition in breast cancer.British journal of cancer · 2009Article
- Article
- Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer.Nature cell biology · 2009Article
- Article
- Real time PCR analyses of expression of E-cadherin, alpha-, beta- and gamma-catenin in human breast cancer for predicting clinical outcome.World journal of surgical oncology · 2008Article
- In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin.British journal of cancer · 2007Article
- The Prognostic Value of E-cadherin Expression in Breast Cancer.International journal of health sciences · 2007Article
- An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ.Breast cancer research : BCR · 2007Article
- A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes.Oncogene · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial cadherin (E-CD) is a member of the cadherin family of cell adhesion molecules and has been implicated as an invasion suppressor molecule in vitro and in vivo. We analysed 174 breast tumours from the Nottingham/Tenovus Breast Cancer Series immunohistochemically for E-CD expression using the mouse monoclonal antibody HECD-1 (Zymed Laboratories Inc.). In normal epithelial cells E-CD was strongly expressed at cell-cell boundaries. 66% of the breast cancers examined had reduced intensity of E-CD expression with 74% having significant reductions in the proportion of E-CD-positive tumour cells. Using a combined intensity/proportion score, significant associations were found between E-CD expression and tumour type (P </= 0.001). ER status (P = 0.026) and histological grade (P = 0.031). Expression of E-CD was not found to be related to recurrence, distant metastases, lymph node stage, vascular invasion, primary tumour size, prognostic group or survival. Thus E-CD expression in human breast cancer appears to have minimal prognostic value, but may have a role as a phenotypic marker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.